The clinical trial application for the replication deficient monkeypox vaccine developed by Chinese biotechnology has been accepted

On July 13, the application for clinical trial of replication defective monkeypox vaccine independently developed by Sinopharm China Biotech Beijing Institute of Biological Products was officially accepted by the Drug Evaluation Center (CDE) of the National Medical Products Administration.Monkeypox is a kind of zoonotic viral disease caused by Monkeypox virus (MPXV), which is characterized by fever, rash and Lymphadenopathy...

Tech >>